Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 17, 2009

Exiqon Expands Portfolio with Norgen's RNA Purification Kits

Exiqon Expands Portfolio with Norgen's RNA Purification Kits

Exiqon to add RNA purification kits to its portfolio

  • Norgen Biotek signed an OEM and supply agreement with Exiqon related to RNA purification kits. The agreement will expand Exiqon's product portfolio of miRNA analysis services.

    Norgen's Total RNA Purification and FFPE RNA Extraction kits isolate total RNA, miRNA, cytoplasmic, and nuclear RNA without the use of phenol extraction steps.

    These will be integrated with Exiqon's miRCURY LNA (locked nucleic acid) product line, which includes an expression-profiling array system, detection probes, knockdown products, and a PCR system.

    "Adding these products to our miRCURY LNA product line is an important step in order to broaden our product portfolio and to fulfill our ambition of being a total solution provider in the field of miRNA analysis," says Henrik M. Pfundheller, vp of sales and marketing for Exiqon.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »